189 related articles for article (PubMed ID: 37898866)
1. Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
Algamal RA; Abu Samra NK; Ellashery RA; Abd-EL-Hameed SAE; Shahin DA
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3577-3584. PubMed ID: 37898866
[TBL] [Abstract][Full Text] [Related]
2. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
Short NJ; Jabbour E
Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
[TBL] [Abstract][Full Text] [Related]
3. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
[TBL] [Abstract][Full Text] [Related]
7. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
8. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of Minimal Residual Disease Detection in Infants With
Stutterheim J; van der Sluis IM; de Lorenzo P; Alten J; Ancliffe P; Attarbaschi A; Brethon B; Biondi A; Campbell M; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Li CK; Lo Nigro L; Locatelli F; Marschalek R; Meyer C; Schrappe M; Stary J; Vora A; Zuna J; van der Velden VHJ; Szczepanski T; Valsecchi MG; Pieters R
J Clin Oncol; 2021 Feb; 39(6):652-662. PubMed ID: 33405950
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
[TBL] [Abstract][Full Text] [Related]
11. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
[TBL] [Abstract][Full Text] [Related]
14. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
15. Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia.
Qin X; Zhang MY; Liu WJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6885-6895. PubMed ID: 30402854
[TBL] [Abstract][Full Text] [Related]
16. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
17. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction.
Cheng SH; Lau KM; Li CK; Chan NP; Ip RK; Cheng CK; Lee V; Shing MM; Leung AW; Ha SY; Cheuk DK; Lee AC; Li CH; Luk CW; Ling SC; Hrusak O; Mejstrikova E; Leung Y; Ng MH
PLoS One; 2013; 8(7):e69467. PubMed ID: 23936021
[TBL] [Abstract][Full Text] [Related]
19. Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
Ceppi F; Rizzati F; Colombini A; Conter V; Cazzaniga G
Expert Rev Hematol; 2021 Sep; 14(9):795-807. PubMed ID: 34374613
[TBL] [Abstract][Full Text] [Related]
20. A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A; Henze G; Roumiantseva J; Budanov O; Belevtsev M; Verzhbitskaya T; Boyakova E; Movchan L; Tsaur G; Fadeeva M; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Fechina L; Aleinikova O; Karachunskiy A
Pediatr Blood Cancer; 2023 Jun; 70(6):e30295. PubMed ID: 36975157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
